^
Association details:
| Biomarker: | EGFR exon 21 deletion + EGFR L858R + MET Exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib
Published date:
08/08/2023
Excerpt:
In this case, we reported a NSCLC patient with EGFR-sensitive combining MET Exon 14 Skipping mutations, who obtained a remarkable curative effect after aumolertinib, especially the CNS lesions have been continuously relieved. This was the first report applied aumolertinib to patients with EGFR and MET co-mutations, which providing us with a reference for treatment of such patients.
